Biomea Fusion Inc (BMEA NASDAQ) stock market data APIs
$1.7307
0.08(4.6%)
as of July 1, 2025
Try our APIs with
free plan!
Biomea Fusion Inc Financial Data Overview
Price chart is built with
Anychart
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Prev. Close
1.7307
Open
1.8092
High
1.8092
Low
1.6422
52 wk Range
1.2905-13.07
Market Cap
98 078 K
Shares Outstanding
57 022 K
EPS
-0.8
Beta
-0.247
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biomea Fusion Inc data using free add-ons & libraries
Get Biomea Fusion Inc Fundamental Data
Biomea Fusion Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -130 927 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.6011
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biomea Fusion Inc News
New
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, ou...
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filin...
Meta, Peloton and Hasbro rise premarket; AstraZeneca falls
Investing.com -- U.S. stock futures edged higher Wednesday, as traders digested the ongoing conflict in the Middle East as well as the conclusion of the latest Federal Reserve meeting. Here are some ...
Biggest stock movers Wednesday: UBS, BTDR, and more
[Mixed group of millennial aged friends discuss investing and cryptocurrency trading] Trevor Williams Stock futures edged higher early Wednesday as investors awaited the Federal Reserve’s interest ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
